MI and PreviDent Varnish on Non Cavitated Interproximal Lesions. Randomised Clinical Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03925740|
Recruitment Status : Active, not recruiting
First Posted : April 24, 2019
Last Update Posted : April 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|Prevention||Drug: MI Varnish Drug: PreviDent Varnish Drug: 1.23% ACP fluoride||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Official Title:||The Effectiveness of MI and PreviDent Varnish on Non Cavitated Interproximal Lesions. Randomised Clinical Trial|
|Actual Study Start Date :||January 1, 2019|
|Estimated Primary Completion Date :||December 1, 2019|
|Estimated Study Completion Date :||March 2020|
Experimental: MI Varnish Group
The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Remineralization protocol, group one will be treated with MI varnish according to the manufacture instructions in first visit and each follow up visits.
Drug: MI Varnish
Application of different varnish materials versus the standard 1.23% ACP fluoride.
Experimental: PreviDent Varnish Group
The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Group two will receive PreviDent varnish according to the manufacture instructions in the first visit and each follow up visits.
Drug: PreviDent Varnish
Active Comparator: 1.23% ACP Control Group
Regular application of ACP for 4 minutes with high volume suction to the whole mouth.
Drug: 1.23% ACP fluoride
1.23% ACP fluoride
- Radiographic outcome [ Time Frame: 1 year ]Incipient lesions either remained the same or worsened.
- Clinical examination [ Time Frame: 1 year ]Lesion cavitation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03925740
|King Adbulaziz University Dental Hospital|
|Jeddah, Makkah, Saudi Arabia, 21589|